Director of Tobacco Regulatory Science Research, Oklahoma Tobacco Research Center, Stephenson Cancer Center; Associate Professor, Department of Pediatrics, University of Oklahoma Health Sciences Center
Dr. Wagener serves as the Director of Tobacco Regulatory Science Research at the Oklahoma Tobacco Research Center. In addition, he is an Associate Professor in the Department of Pediatrics at the University of Oklahoma Health Sciences Center, College of Medicine. Dr. Wagener also holds adjunct appointments in the Graduate College in Clinical and Translational Sciences, Department of Biostatistics and Epidemiology at OUHSC and the Department of Psychiatry, and Department of Psychology at Oklahoma State University.
He received his doctoral training in Clinical Psychology with a specialization in health psychology/behavioral medicine from Oklahoma State University in 2010. He completed his psychology residency and T32 postdoctoral fellowship in cardiovascular behavioral medicine at the Warren Alpert Medical School of Brown University and the Centers of Behavioral and Preventive Medicine in 2011. Dr. Wagener joined the faculty in the Department of Pediatrics and OTRC in 2011. He is a licensed psychologist and directed the behavioral sleep medicine clinic at OU Children’s Hospital from 2011 to 2016.
Dr. Wagener’s research program focuses on tobacco regulatory science, with a specialized focus on evaluating the pharmacological and behavioral use patterns of non-cigarette tobacco products, such as electronic cigarettes, dissolvable tobacco, and hookah. He also has expertise developing and testing motivational enhancement-based smoking cessation and secondhand smoke reduction interventions for children of parents who smoke. His work has been continuously funded by the NIH and/or FDA since joining OUHSC.
Dr. Wagener is committed to mentoring and training the next generation of psychologist and tobacco researchers. Within the Department of Pediatrics, he co-directed the Residents Research Methods Seminar Series and has trained almost 40 graduate students, psychology residents and fellows, medical students, residents and fellows, and junior faculty in sleep medicine. In his role overseeing the OTRC Training Program, Dr. Wagener has mentored/co-mentored numerous student-led projects as well as graduate students who have gone on to prestigious psychology residencies, fellowships, and academic faculty positions. He currently serves as the primary sponsor for a NIDA F31 (Eleanor Leavens, MS) and co-mentor for a NIDA R36 (Dana Mowls, MPH).
Oklahoma State University, Stillwater, OK, PhD, 2010, Clinical PsychologyThe Oklahoma State University, Stillwater, OK, MS, 2005, Clinical Psychology
College of Wooster, Wooster, OH, BS, 2002, Psychology & Philosophy
Clinical Psychology Residency, Behavioral Medicine Track, Brown Medical School, Providence, RI, 7/2009−6/2010
Postdoctoral Fellowship, NHLBI T32, Cardiovascular Behavioral Medicine, Brown Medical School, Providence, RI, 7/2010−11/2011
Wagener, T.L. (Prinicpal Investigator), "The Impact of Waterpipe Tobacco Sweeteners on Waterpipe Smoking Intentions, Perceptions, Patterns, and Toxicant Exposure"
NIDA/FDA R03DA041928-02S1, 09/01/2017 – 08/31/2018
Total Cost: $62,074
Wagener, T. L. (Co-Investigator), "A Naturalistic Nationwide Randomized Study of e-Cigarette Uptake and Consequences"
NCI R01 CA210625, 08/01/2017 – 07/31/2022
Total Cost: $2,616,376
Wagener, T. L. (Co-Investigator), "Enhanced E-cigarette Coaching Intervention for Dual Users of Cigarettes and E-cigarettes"
NIH/NIDA R21 DA042960, 09/01/2017-07/31/2019
Total Cost: $401,500
Wagener, T. L. (Principal Investigator), "Examination of First and Second Generation E-cigarettes," NIH/NCI - R01 CA194158-01
Total Direct Costs: $3,365,226
September 30, 2016 - August 31, 2021
Wagener, T. L. (Principal Investigator), "The Impact of Waterpipe Tobacco Flavors on Waterpipe Smoking Intentions, Perceptions, Patterns, and Toxicant Exposure"
NIH/NIDA/FDA - R03DA041928
Total Direct Costs: $222,000.00
September 15, 2016 - August 31, 2018
Wagener, T. L. (Co-Investigator), "Feasibility Studies to Build Collaborative Partnerships in Cancer Research"
NIH/NCI - P20CA202921
Total Direct Costs: $641,486.00
October 1, 2015 - September 30, 2019
Wagener, T. L. (Co-Investigator), "A novel molecular assay for early detection and assessment of cancer risk"
NIH/NCI - R33CA202898
Total Direct Costs: $641,486.00
April 8, 2016 - March 31, 2019
Wagener, T. L. (Primary Sponsor)*, Leavens, E. L. (Principal Investigator)*, "Effect of Alcohol Use on Waterpipe Smoking Patterns and Toxicant Exposure"
NIH/NIDA - F31 DA042523
Total Direct Costs: $86,146.00
July 15, 2016 - June 30, 2018
Wagener, T. L. (Co-Mentor/Co-Investigator), "Nicotine Metabolism in American Indian Smokers and Electronic Cigarette Users"
NIH/NIDA - R36DA042208
Total Direct Costs: $125,768.00
June 1, 2016 - May 31, 2018
Wagener, T. L. (Co-Investigator), "Neurobehavioral Assessment of Reward Sensitivity in Young Smokers”
NIH/NIDA - R21DA038001
Total Direct Costs: $370,000.00
July 15, 2015 - June 30, 2017
Wagener, T. L. (Principal Investigator), "Examining the Efficacy of Tobacco Harm Reduction" NCTS - Clinical Research Loan Repayment Program
October 1, 2013 - September 30, 2017
Wagener, T.L. (Co-Investigator) “Oklahoma Tobacco Research Center Expansion Grant”
Tobacco Settlement Endowment Trust 092-016-0002
Completed Funding (Past 5 years)
Wagener, T. L. (Principal Investigator), "Novel Methods to Reduce Children's Secondhand Smoke Exposure"
NIH/NCI - R21 CA164521-
Total Direct Costs: $412,337.00
January 15, 2013 - December 31, 2015
Wagener, T. L. (Principal Investigator), "Evaluating a Sequential Adaptive Smoking Cessation Intervention"
NIH/NIGMS - U54 GM104938
Total Direct Costs: $123,252.00
July 1, 2014 - June 30, 2015
Wagener, T. L. (Co-Investigator), "An Exploratory Study of Vape Shop Marketing Practices in Seven Cities"
FDA/NIDA TCORS P50 DA-036128-01
Total Direct Costs: $75,000.00
November 1, 2014 - October 31, 2015
Wagener, T. L. (Consultant), "A Randomized Trial of E-cigarettes: Natural Uptake, Patterns and Impact of Use"
NIH/NIDA – R21DA037407
October 1, 2014 - September 30, 2016
Wagener, T. L. (Co-Investigator), "Matching Brief Smoking Interventions to Stage of Change"
OCAST HR 12-020
Total Direct Costs: $134,419.00
July 1, 2012 - June 30, 2015
Wagener, T. L. (Co-Investigator), "Secondhand and Thirdhand Smoke Exposure in Children with Asthma,"
University of Florida Clinical and Translational Science Institute
Total Direct Costs: $17,500.00
July 1, 2015 - June 30, 2016
Wagener, T. L., Floyd, E. L., Stepanov, I., Driskill, L. M., Frank, S. G., Meier, E., Leavens EL, Tackett AP, Molina N, & Queimado, L. (2016). Have combustible cigarettes met their match? The nicotine delivery profiles and harmful constituent exposures of second-generation and third-generation electronic cigarette users. Tobacco Control. doi:10.1136/tobaccocontrol-2016-053041
Leavens EL, Driskill LM, Molina N, Eissenberg T, Shihadeh A, Brett E, Floyd E, Wagener TL. (2017) Comparison of a preferred versus non-preferred waterpipe tobacco flavour: subjective experience, smoking behaviour and toxicant exposure. Tobacco Control. [epub ahead of print] doi: 10.1136/tobaccocontrol-2016-053344.
Leavens, E. L., Brett, E. I., Frank, S., Shaikh, R. A., Leffingwell, T. R., Croff, J. M., & Wagener, T. L. (2017). Association between breath alcohol concentration and waterpipe lounge patrons’ carbon monoxide exposure: A field investigation. Drug and Alcohol Dependence, 170, 152-155.
Wagener, T. L., Shaikh, R. A., Meier, E., Tackett, A. P., Tahirkheli, N. N., Leavens, E. L., & Driskill, L. (2016). Examining the Smoking and Vaping Behaviors and Preferences of Vape Shop Customers. Tobacco Prevention & Cessation, 2(Supplement). doi:10.18332/tpc/65150
Wagener, T. L., Meier, E., Tackett, A. P., Matheny, J. D., & Pechacek, T. F. (2016). A Proposed Collaboration Against Big Tobacco: Common Ground Between the Vaping and Public Health Community in the United States. Nicotine & Tobacco Research, 18(5), 730-736. doi:10.1093/ntr/ntv241
Busch, A. M., Leavens, E. L.,Wagener, T. L., Buckley, M. L., & Tooley, E. M. (2016). Prevalence, Reasons for Use, and Risk Perception of Electronic Cigarettes Among Post-Acute Coronary Syndrome Smokers. J Cardiopulm Rehabil Prev. doi:10.1097/HCR.0000000000000179
James, S. A., Meier, E. M., Wagener, T. L., Smith, K. M., Neas, B. R., & Beebe, L. A. (2016). E-Cigarettes for Immediate Smoking Substitution in Women Diagnosed with Cervical Dysplasia and Associated Disorders. Int J Environ Res Public Health, 13(3). doi:10.3390/ijerph13030288
Lechner, W. V., Meier, E., Wiener, J. L., Grant, D. M., Gilmore, J., Judah, M. R., . . . Wagener, T. L. (2015). The comparative efficacy of first- versus second-generation electronic cigarettes in reducing symptoms of nicotine withdrawal. Addiction, 110(5), 862-867. doi:10.1111/add.12870
Wagener, T. L., Tackett, A. P., & Borrelli, B. (2015). Caregivers' interest in using smokeless tobacco products: Novel methods that may reduce children's exposure to secondhand smoke. J Health Psychoogyl. doi:10.1177/1359105315576347
Lechner, W. V., Tackett, A. P., Grant, D. M., Tahirkheli, N. N., Driskill, L. M., & Wagener, T. L. (2015). Effects of duration of electronic cigarette use. Nicotine & Tobacco Research, 17(2), 180-185. doi:10.1093/ntr/ntu061
Meier, E. M., Tackett, A. P., Miller, M. B., Grant, D. M., & Wagener, T. L. (2015). Which nicotine products are gateways to regular use? First-tried tobacco and current use in college students. American Journal of Preventive Medicine, 48(1 Suppl 1), S86-93. doi:10.1016/j.amepre.2014.09.018
Tackett, A. P., Lechner, W. V., Meier, E., Grant, D. M., Driskill, L. M., Tahirkheli, N. N., & Wagener, T. L. (2015). Biochemically verified smoking cessation and vaping beliefs among vape store customers. Addiction, 110(5), 868-874. doi:10.1111/add.12878